Core Viewpoint - Autonomix Medical, Inc. has developed innovative technologies aimed at revolutionizing the diagnosis and treatment of diseases involving the nervous system, with a focus on pancreatic cancer-related pain management [2][4]. Group 1: Patent and Technology Development - The company has a growing global patent portfolio with over 120 patents, including 80 issued patents and over 40 pending applications [3][5]. - The recently issued U.S. patent 12,064,256 (the "256 patent") covers systems and methods for treating cancer and augmenting organ function, specifically targeting pancreatic cancer-related pain [3][4]. - Autonomix's first-in-class catheter-based microchip sensing array technology can detect and differentiate neural signals with approximately 3,000 times greater sensitivity than existing technologies [2][6]. Group 2: Clinical Studies and Results - A preclinical study demonstrated a statistically significant reduction in metastases and tumor mass through targeted nerve ablation, indicating the potential impact of neural pathways in pancreatic cancer [4][6]. - The ongoing proof-of-concept human clinical trial is focused on pain reduction from the ablation of target nerves near the pancreas, with plans for additional studies to evaluate the clinical application of the technology [4][10]. Group 3: Future Directions and Applications - The company aims to explore the potential of its ablation technology to slow pancreatic cancer growth and metastasis based on positive preclinical results [4][10]. - The technology platform is designed to address various disease categories, including chronic pain management, cardiology, and hypertension, beyond its initial focus on cancer pain [10].
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology